Observational study on precision medicine for advanced cancer patients
Prospective Observational Study of a Precision Medicine Approach in Patients With Advanced Cancer
This study is testing how personalized treatments based on genetic information can help people with advanced cancer feel better and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 1 site (Berlin) |
| Trial ID | NCT05926284 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with advanced cancer who are undergoing extensive molecular sequencing as part of a precision oncology program at Charité University Medicine in Berlin. Participants will be registered and monitored to evaluate the effectiveness of individualized therapies and the clinical relevance of identified molecular alterations. The study aims to gather data on the frequency of these alterations and the utility of novel molecular analysis tools in guiding treatment decisions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with advanced cancer who can provide informed consent and are eligible for targeted treatments based on molecular analysis.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective, personalized treatment options for patients with advanced cancer.
How similar studies have performed: Other studies utilizing precision medicine approaches in oncology have shown promising results, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * advanced cancer * ability to give written informed consent * performance status allows initiation of a potential targeted treatment after molecular analysis * molecular analysis has been done or planned Exclusion Criteria: \- unable to give written informed consent
Where this trial is running
Berlin
- Charité Comprehensive Cancer Center — Berlin, Germany (Recruiting)
Study contacts
- Study coordinator: Damian T Rieke, MD
- Email: cccc@charite.de
- Phone: +49 (0)30 450 564 222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.